Luke Lee

Luke Lee

Company: 3T Biosciences

Job title: CEO, Co-Founder


Designing Best in Class TCR Cell Therapies Against Novel Antigens 12:20 pm

• Identifying the nuances of neoantigen TCR-based therapies to allow acceleration to the clinic • Importance of diversity for identifying first in class targets and best in class T cell receptors while minimizing off-target toxicity. • Characterizing T cell receptors with the ideal binding profile. • Utilization of a mass spectrometry independent yeast display platform…Read more

day: Focus Day

Industry Panel to Address the Most Critical Questions for this Nascent & Emerging Therapeutic 8:40 am

• What is the best neoantigen prediction platform? • What is the most robust approach to identifying the “right” neoantigen? • How to best deliver a neoantigen therapy, vaccine or cell therapy? • What type of vaccine, cell based, virus, RNA, DNA, peptide? • Which approach is safer and more efficacious? • Should the focus be…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.